Combinatorial ablation and immunotherapy: Difference between revisions
Content deleted Content added
No edit summary |
hyperthermal immunology |
||
| Line 1: | Line 1: | ||
'''Combinatorial ablation and immunotherapy''' is an oncological treatment that combines various tumor-ablation techniques with immunotherapy treatment.<ref>{{Cite journal | author = Dupuy, et al. | title = Thermal ablation of tumours: biological mechanisms and advances in therapy.| year = 2014|| doi = 10.1038/nrc3672| url=http://www.nature.com/nrc/journal/v14/n3/abs/nrc3672.html}} </ref><ref name=hindawi9251375>{{Cite journal | title = Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?| year = 2015| url=https://www.hindawi.com/journals/grp/2016/9251375/}}</ref><ref name="interventionalnews"> {{Cite web | title = Immunotherapy could transform systemic power of locoregional IO treatments| year = 2016| url=https://interventionalnews.com/immunotherapy-could-transform-systemic-power-of-locoregional-io-treatments/}} </ref><ref> {{Cite book | title = Cancer Immunology and Immunotherapy| year = 2016| url=https://books.google.com/books?id=XSM545kh36oC&pg=PA218/|page=218}}</ref> Combining ablation therapy of tumors with immunotherapy enhances the immunostimulating response and has synergistic effects for curative metastatic cancer treatment.<ref name=hindawi9251375/><ref name="interventionalnews"/> Various ablative techniques are utilized including [[cryoimmunology|cryoablation]], radiofrequency ablation, laser ablation, [[Photoimmunotherapy|photodynamic ablation]], [[hyperthermia therapy]], [[HIFU]].<ref> {{Cite web | author = Prof. Yona Keisari | title = Development of Cancer Treatments Integrating Radiotherapy or Electrochemical Ablation and Immunotherapy | url=https://en-med.tau.ac.il/research_ablation}}</ref> Thus, combinatorial ablation of tumors and immunotherapy is a way of achieving [[autologous]], [[in-vivo]] tumor [[lysate]] vaccine and treat [[metastatic]] disease. |
'''Combinatorial ablation and immunotherapy''' is an oncological treatment that combines various tumor-ablation techniques with immunotherapy treatment.<ref>{{Cite journal | author = Dupuy, et al. | title = Thermal ablation of tumours: biological mechanisms and advances in therapy.| year = 2014|| doi = 10.1038/nrc3672| url=http://www.nature.com/nrc/journal/v14/n3/abs/nrc3672.html}} </ref><ref name=hindawi9251375>{{Cite journal | title = Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?| year = 2015| url=https://www.hindawi.com/journals/grp/2016/9251375/}}</ref><ref name="interventionalnews"> {{Cite web | title = Immunotherapy could transform systemic power of locoregional IO treatments| year = 2016| url=https://interventionalnews.com/immunotherapy-could-transform-systemic-power-of-locoregional-io-treatments/}} </ref><ref> {{Cite book | title = Cancer Immunology and Immunotherapy| year = 2016| url=https://books.google.com/books?id=XSM545kh36oC&pg=PA218/|page=218}}</ref> Combining ablation therapy of tumors with immunotherapy enhances the immunostimulating response and has synergistic effects for curative metastatic cancer treatment.<ref name=hindawi9251375/><ref name="interventionalnews"/> Various ablative techniques are utilized including [[cryoimmunology|cryoablation]], radiofrequency ablation, laser ablation, [[Photoimmunotherapy|photodynamic ablation]], [[hyperthermia therapy]], [[HIFU]].<ref> {{Cite web | author = Prof. Yona Keisari | title = Development of Cancer Treatments Integrating Radiotherapy or Electrochemical Ablation and Immunotherapy | url=https://en-med.tau.ac.il/research_ablation}}</ref><ref> {{Cite journal | year= 2003 | title = Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. | url=https://www.ncbi.nlm.nih.gov/pubmed/12824927}}</ref> <ref> {{Cite journal | author =Xiaoming Yang | year = 2016 | title = Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy | doi = 10.18632/oncotarget.11346 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323137/}}</ref> <ref> {{Cite journal | year= 2000 | title = Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter. | url=https://www.ncbi.nlm.nih.gov/pubmed/11119417}}</ref><ref> {{Cite journal | year= 2016 | title = Combination by Hyperthermia and Immunotherapy: DC Therapy and Hyperthermia. | url=https://link.springer.com/chapter/10.1007%2F978-981-10-0719-4_30}}</ref><ref> {{Cite journal | journal=Austin Oncol Case Rep |year= 2017 | title = A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination. | url=http://www.iozk.de/aktuelles/iozk_austin_oncology_case_reports_2017.pdf}}</ref> Thus, combinatorial ablation of tumors and immunotherapy is a way of achieving [[autologous]], [[in-vivo]] tumor [[lysate]] vaccine and treat [[metastatic]] disease. |
||
==Mechanism of Action== |
==Mechanism of Action== |
||
Partially or entirely ablating primary or secondary metastatic tumors induces necrosis of tumor cells, resulting in the release of antigens and presentation of antigens to the immune system. The released tumor antigens help activate anti-tumor T cells, which can destroy remaining malignant cells in local and distant tumors. Combining [[Cancer immunotherapy|immunotherapy]] (ie: checkpoint inhibitors, [[Chimeric antigen receptor|CAR-T cell therapy]]) and vaccine adjuvants (ie: [[interferon]], [[saponin]]) with ablation synergizes the immune reaction, and can treat metastatic disease with curative intent. <ref name="interventionalnews"/> <ref>{{cite journal | year = 2015 |title = Cryo-thermal therapy elicits potent anti-tumor immunity.| url =http://www.nature.com/articles/srep27136}}</ref><ref>Cryosurgery initiates inflammation and leaves tumor-specific antigens intact, which may induce an anti-tumor immune response.{{cite journal | year = 2005 |title = Immunologic response to cryoablation of breast cancer. | author = Sabel | pmc=4115762 | pmid=25083502 | doi=10.3978/j.issn.2227-684X.2014.03.04 | volume=3 | journal=Gland Surg | pages=88–93}}</ref> |
Partially or entirely ablating primary or secondary metastatic tumors induces necrosis of tumor cells, resulting in the release of antigens and presentation of antigens to the immune system. The released tumor antigens help activate anti-tumor T cells, which can destroy remaining malignant cells in local and distant tumors. Combining [[Cancer immunotherapy|immunotherapy]] (ie: checkpoint inhibitors, [[Chimeric antigen receptor|CAR-T cell therapy]]) and vaccine adjuvants (ie: [[interferon]], [[saponin]]) with ablation synergizes the immune reaction, and can treat metastatic disease with curative intent. <ref name="interventionalnews"/> <ref>{{cite journal | year = 2015 |title = Cryo-thermal therapy elicits potent anti-tumor immunity.| url =http://www.nature.com/articles/srep27136}}</ref><ref>Cryosurgery initiates inflammation and leaves tumor-specific antigens intact, which may induce an anti-tumor immune response.{{cite journal | year = 2005 |title = Immunologic response to cryoablation of breast cancer. | author = Sabel | pmc=4115762 | pmid=25083502 | doi=10.3978/j.issn.2227-684X.2014.03.04 | volume=3 | journal=Gland Surg | pages=88–93}}</ref> |
||
<ref>{{cite journal | year = 2005 |title = Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity.| url =http://clincancerres.aacrjournals.org/content/11/13/4955}}</ref> <ref>{{cite journal | year = 2016 |title = Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response.| journal = Gastroenterol Res Pract. | doi=10.1155/2016/9251375 | volume=2016 | pages=1–11}}</ref> |
<ref>{{cite journal | year = 2005 |title = Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity.| url =http://clincancerres.aacrjournals.org/content/11/13/4955}}</ref> <ref>{{cite journal | year = 2016 |title = Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response.| journal = Gastroenterol Res Pract. | doi=10.1155/2016/9251375 | volume=2016 | pages=1–11}}</ref><ref> {{Cite journal | year= 2012 | title = Nanoparticle-mediated hyperthermia in cancer therapy. | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323111/}}</ref> |
||
== See also == |
== See also == |
||
Revision as of 11:29, 5 May 2017
Combinatorial ablation and immunotherapy is an oncological treatment that combines various tumor-ablation techniques with immunotherapy treatment.[1][2][3][4] Combining ablation therapy of tumors with immunotherapy enhances the immunostimulating response and has synergistic effects for curative metastatic cancer treatment.[2][3] Various ablative techniques are utilized including cryoablation, radiofrequency ablation, laser ablation, photodynamic ablation, hyperthermia therapy, HIFU.[5][6] [7] [8][9][10] Thus, combinatorial ablation of tumors and immunotherapy is a way of achieving autologous, in-vivo tumor lysate vaccine and treat metastatic disease.
Mechanism of Action
Partially or entirely ablating primary or secondary metastatic tumors induces necrosis of tumor cells, resulting in the release of antigens and presentation of antigens to the immune system. The released tumor antigens help activate anti-tumor T cells, which can destroy remaining malignant cells in local and distant tumors. Combining immunotherapy (ie: checkpoint inhibitors, CAR-T cell therapy) and vaccine adjuvants (ie: interferon, saponin) with ablation synergizes the immune reaction, and can treat metastatic disease with curative intent. [3] [11][12] [13] [14][15]
See also
References
- ^ Dupuy; et al. (2014). "Thermal ablation of tumours: biological mechanisms and advances in therapy". doi:10.1038/nrc3672.
{{cite journal}}: Cite has empty unknown parameter:|1=(help); Cite journal requires|journal=(help); Explicit use of et al. in:|author=(help) - ^ a b "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?". 2015.
{{cite journal}}: Cite journal requires|journal=(help) - ^ a b c "Immunotherapy could transform systemic power of locoregional IO treatments". 2016.
- ^ Cancer Immunology and Immunotherapy. 2016. p. 218.
- ^ Prof. Yona Keisari. "Development of Cancer Treatments Integrating Radiotherapy or Electrochemical Ablation and Immunotherapy".
- ^ "Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma". 2003.
{{cite journal}}: Cite journal requires|journal=(help) - ^ Xiaoming Yang (2016). "Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy". doi:10.18632/oncotarget.11346.
{{cite journal}}: Cite journal requires|journal=(help) - ^ "Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter". 2000.
{{cite journal}}: Cite journal requires|journal=(help) - ^ "Combination by Hyperthermia and Immunotherapy: DC Therapy and Hyperthermia". 2016.
{{cite journal}}: Cite journal requires|journal=(help) - ^ "A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination" (PDF). Austin Oncol Case Rep. 2017.
- ^ "Cryo-thermal therapy elicits potent anti-tumor immunity". 2015.
{{cite journal}}: Cite journal requires|journal=(help) - ^ Cryosurgery initiates inflammation and leaves tumor-specific antigens intact, which may induce an anti-tumor immune response.Sabel (2005). "Immunologic response to cryoablation of breast cancer". Gland Surg. 3: 88–93. doi:10.3978/j.issn.2227-684X.2014.03.04. PMC 4115762. PMID 25083502.
- ^ "Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity". 2005.
{{cite journal}}: Cite journal requires|journal=(help) - ^ "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response". Gastroenterol Res Pract. 2016: 1–11. 2016. doi:10.1155/2016/9251375.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ "Nanoparticle-mediated hyperthermia in cancer therapy". 2012.
{{cite journal}}: Cite journal requires|journal=(help)
